J Korean Med Assoc.  2018 Jan;61(1):49-54. 10.5124/jkma.2018.61.1.49.

Treatment and prophylaxis of influenza

• Lee JS

• KMID: 2405136
• DOI: http://doi.org/10.5124/jkma.2018.61.1.49

Abstract

Influenza is an acute respiratory disease caused by the influenza virus. Each year, it causes a significant disease burden, especially in older adults. Furthermore, influenza pandemics occasionally occur because of antigenic change. Common signs and symptoms of influenza include fever, cough, sore throat, headache, myalgia, and runny nose. Severe cases may progress to pneumonia, which causes shortness of breath, tachycardia, hypotension, and the need for supportive respiratory interventions. Mild cases are self-limited and supportive care is sufficient. Antiviral treatment shortens the clinical course if it is administered within 48 hours from the onset of disease. Neuraminidase inhibitors, such as oseltamivir, zanamivir, and peramivir, are widely used. Although annual vaccination is the best means of prevention, its effectiveness can vary from year to year and among different age and risk groups.

Keyword

Influenza, human; Therapeutics; Vaccination

MeSH Terms

Adult
Cough
Dyspnea
Fever
Headache
Humans
Hypotension
Influenza, Human*
Myalgia
Neuraminidase
Nose
Orthomyxoviridae
Oseltamivir
Pandemics
Pharyngitis
Pneumonia
Tachycardia
Vaccination
Zanamivir
Neuraminidase
Oseltamivir
Zanamivir

Reference

1. Saunders-Hastings PR, Krewski D. Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission. Pathogens. 2016; 5:pii: E66.

2. Korean Association for the Study of Infectious Diseases. Infectious diseases. 2nd ed. Seoul: Koonja;2014.

3. Paules C, Subbarao K. Influenza. Lancet. 2017; 390:697–708.

4. Zhao M, Wang L, Li S. Influenza A virus-host protein interactions control viral pathogenesis. Int J Mol Sci. 2017; 18:pii: E1673.

5. Byrd-Leotis L, Cummings RD, Steinhauer DA. The interplay between the host receptor and influenza virus hemagglutinin and neuraminidase. Int J Mol Sci. 2017; 18:pii: E1541.

6. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature. 2006; 440:435–436.

7. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A. 2004; 101:4620–4624.

8. Walther T, Karamanska R, Chan RW, Chan MC, Jia N, Air G, Hopton C, Wong MP, Dell A, Malik Peiris JS, Haslam SM, Nicholls JM. Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. PLoS Pathog. 2013; 9:e1003223.

9. Franca M, Stallknecht DE, Howerth EW. Expression and distribution of sialic acid influenza virus receptors in wild birds. Avian Pathol. 2013; 42:60–71.

10. Greatorex JS, Digard P, Curran MD, Moynihan R, Wensley H, Wreghitt T, Varsani H, Garcia F, Enstone J, Nguyen-Van-Tam JS. Survival of influenza A(H1N1) on materials found in households: implications for infection control. PLoS One. 2011; 6:e27932.

11. Cowling BJ, Ip DK, Fang VJ, Suntarattiwong P, Olsen SJ, Levy J, Uyeki TM, Leung GM, Malik Peiris JS, Chotpitayasunondh T, Nishiura H, Mark Simmerman J. Aerosol transmission is an important mode of influenza A virus spread. Nat Commun. 2013; 4:1935.

12. Wong BC, Lee N, Li Y, Chan PK, Qiu H, Luo Z, Lai RW, Ngai KL, Hui DS, Choi KW, Yu IT. Possible role of aerosol transmission in a hospital outbreak of influenza. Clin Infect Dis. 2010; 51:1176–1183.

13. Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008; 121:258–264.

14. Puig-Barbera J, Burtseva E, Yu H, Cowling BJ, Badur S, Kyncl J, Sominina A. GIHSN. Influenza epidemiology and influenza vaccine effectiveness during the 2014-2015 season: annual report from the Global Influenza Hospital Surveillance Network. BMC Public Health. 2016; 16:Suppl 1. 757.

15. Su S, Gu M, Liu D, Cui J, Gao GF, Zhou J, Liu X. Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. Trends Microbiol. 2017; 25:713–728.

16. Esposito S, Daleno C, Baldanti F, Scala A, Campanini G, Taroni F, Fossali E, Pelucchi C, Principi N. Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus. Virol J. 2011; 8:349.

17. Boivin G, Hardy I, Tellier G, Maziade J. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis. 2000; 31:1166–1169.

18. Peaper DR, Landry ML. Rapid diagnosis of influenza: state of the art. Clin Lab Med. 2014; 34:365–385.

19. Kim DK, Poudel B. Tools to detect influenza virus. Yonsei Med J. 2013; 54:560–566.

20. Operario DJ, Moser MJ, St George K. Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus. J Clin Microbiol. 2010; 48:3517–3524.

21. Higgins AD, Shaw CJ, Johnson JG, Navarro A, Chapman NA, Ewers SD, Stockwell JW, Carpenter JM, Olivo PD, Miao LY. Monoclonal antibody kit for identification of the novel 2009 H1N1 influenza A virus. J Clin Microbiol. 2010; 48:2677–2682.

22. Al Johani SM, Al Balawi M, Al Alwan B, Al Hefdhi R, Hajeer A. Validity of two rapid point of care influenza tests and direct fluorecence assay in comparison of real time PCR for swine of origin Influenza virus. J Infect Public Health. 2011; 4:7–11.

23. Choi WS, Noh JY, Huh JY, Kee SY, Jeong HW, Lee J, Song JY, Cheong HJ, Kim WJ. The clinical usefulness of the SD Bioline Influenza Antigen Test® for detecting the 2009 influenza A (H1N1) virus. Yonsei Med J. 2011; 52:683–685.

24. Tsao KC, Kuo YB, Huang CG, Chau SW, Chan EC. Performance of rapid-test kits for the detection of the pandemic influenza A/H1N1 virus. J Virol Methods. 2011; 173:387–389.

25. Ge Y, Cui L, Qi X, Shan J, Shan Y, Qi Y, Wu B, Wang H, Shi Z. Detection of novel swine origin influenza A virus (H1N1) by real-time nucleic acid sequence-based amplification. J Virol Methods. 2010; 163:495–497.

26. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015; 385:1729–1737.

27. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014; (4):CD008965.

28. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Baez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, Gerardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoger PH, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikic D, Mohn KG, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodriguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skret-Magierlo J, Stephan F, Talarek E, Tang JW, To KK, Torres A, Torun SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RT, Zarogoulidis P, Nguyen-Van-Tam JS. PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014; 2:395–404.

29. Okoli GN, Otete HE, Beck CR, Nguyen-Van-Tam JS. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One. 2014; 9:e113633.

30. Naesens L, Stevaert A, Vanderlinden E. Antiviral therapies on the horizon for influenza. Curr Opin Pharmacol. 2016; 30:106–115.

31. Krol E, Rychlowska M, Szewczyk B. Antivirals: current trends in fighting influenza. Acta Biochim Pol. 2014; 61:495–504.

32. Houser K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015; 17:295–300.

33. Singanayagam A, Zambon M, Lalvani A, Barclay W. Urgent challenges in implementing live attenuated influenza vaccine. Lancet Infect Dis. 2017; 08. 02. DOI: 10.1016/S1473-3099(17)30360-2. [Epub].

34. Chan TC, Fan-Ngai Hung I, Ka-Hay Luk J, Chu LW, Hon-Wai Chan F. Effectiveness of influenza vaccination in institutionalized older adults: a systematic review. J Am Med Dir Assoc. 2014; 15:226.e1–226.e6.

35. Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2014; (3):CD001269.

36. Lee WJ, Chen LK, Tang GJ, Lan TY. The impact of influenza vaccination on hospitalizations and mortality among frail older people. J Am Med Dir Assoc. 2014; 15:256–260.

37. Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review. Hum Vaccin Immunother. 2015; 11:553–563.

38. Krammer F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J. 2015; 10:690–701.